258 related articles for article (PubMed ID: 23652902)
1. Case experience of 308-nm excimer laser therapy compatibility with PUVA and oral bexarotene for the treatment of cutaneous lesions in mycosis fungoides.
Huang J; Cowper S; Moss J; Girardi M
J Drugs Dermatol; 2013 Apr; 12(4):487-9. PubMed ID: 23652902
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of bexarotene combined with psoralen-ultraviolet A (PUVA) compared with PUVA treatment alone in stage IB-IIA mycosis fungoides: final results from the EORTC Cutaneous Lymphoma Task Force phase III randomized clinical trial (NCT00056056).
Whittaker S; Ortiz P; Dummer R; Ranki A; Hasan B; Meulemans B; Gellrich S; Knobler R; Stadler R; Karrasch M
Br J Dermatol; 2012 Sep; 167(3):678-87. PubMed ID: 22924950
[TBL] [Abstract][Full Text] [Related]
3. Treatment of mycosis fungoides with oral bexarotene combined with PUVA.
Stern DK; Lebwohl M
J Drugs Dermatol; 2002 Sep; 1(2):134-6. PubMed ID: 12847736
[TBL] [Abstract][Full Text] [Related]
4. Plaque stage mycosis fungoides treated with bexarotene at low dosage and UVB-NB.
D'Acunto C; Gurioli C; Neri I
J Dermatolog Treat; 2010 Jan; 21(1):45-8. PubMed ID: 19603308
[TBL] [Abstract][Full Text] [Related]
5. Treatment of mycosis fungoides with bexarotene and psoralen plus ultraviolet A.
Coors EA; Von den Driesch P
Br J Dermatol; 2005 Jun; 152(6):1379-81. PubMed ID: 15949024
[No Abstract] [Full Text] [Related]
6. Psoralen plus long-wave UV-A (PUVA) and bexarotene therapy: An effective and synergistic combined adjunct to therapy for patients with advanced cutaneous T-cell lymphoma.
McGinnis KS; Shapiro M; Vittorio CC; Rook AH; Junkins-Hopkins JM
Arch Dermatol; 2003 Jun; 139(6):771-5. PubMed ID: 12810509
[TBL] [Abstract][Full Text] [Related]
7. Juvenile mycosis fungoides treated with bexarotene and PUVA.
Rodríguez-Vázquez M; García-Arpa M; González-García J
Int J Dermatol; 2007 Jan; 46(1):99-102. PubMed ID: 17214731
[TBL] [Abstract][Full Text] [Related]
8. Bexarotene and its potential role in the treatment of neurological disorders: beyond its role as an anti-cancer agent.
Kapoor S
J Drugs Dermatol; 2014 Mar; 13(3):240. PubMed ID: 24595564
[No Abstract] [Full Text] [Related]
9. Safety and efficacy of low-dose bexarotene and PUVA in the treatment of patients with mycosis fungoides.
Papadavid E; Antoniou C; Nikolaou V; Siakantaris M; Vassilakopoulos TP; Stratigos A; Stavrianeas N; Katsambas A
Am J Clin Dermatol; 2008; 9(3):169-73. PubMed ID: 18429646
[TBL] [Abstract][Full Text] [Related]
10. Treatment of mycosis fungoides with denileukin diftitox and oral bexarotene.
Talpur R; Duvic M
Clin Lymphoma Myeloma; 2006 May; 6(6):488-92. PubMed ID: 16796781
[TBL] [Abstract][Full Text] [Related]
11. Topical bexarotene for psoralen plus ultraviolet A-induced photodamage.
Deonizio JM; Vaghani SP; Guitart J
J Am Acad Dermatol; 2013 Aug; 69(2):e96-8. PubMed ID: 23866897
[No Abstract] [Full Text] [Related]
12. Narrow band UVB (311 nm), psoralen UVB (311 nm) and PUVA therapy in the treatment of early-stage mycosis fungoides: a right-left comparative study.
El-Mofty M; El-Darouty M; Salonas M; Bosseila M; Sobeih S; Leheta T; Nada H; Tawdy A; Amin I; El-Enany G
Photodermatol Photoimmunol Photomed; 2005 Dec; 21(6):281-6. PubMed ID: 16313238
[TBL] [Abstract][Full Text] [Related]
13. Folliculotropic mycosis fungoides: clinicopathological features and outcome in a series of 20 cases.
Muniesa C; Estrach T; Pujol RM; Gallardo F; Garcia-Muret P; Climent J; Servitje O
J Am Acad Dermatol; 2010 Mar; 62(3):418-26. PubMed ID: 20079954
[TBL] [Abstract][Full Text] [Related]
14. Excimer laser in the treatment of mycosis fungoides.
Deaver D; Cauthen A; Cohen G; Sokol L; Glass F
J Am Acad Dermatol; 2014 Jun; 70(6):1058-60. PubMed ID: 24775402
[TBL] [Abstract][Full Text] [Related]
15. Results of a prospective phase II trial with oral low-dose bexarotene plus photochemotherapy (PUVA) in refractory and/or relapsed patients with mycosis fungoides.
Rupoli S; Canafoglia L; Goteri G; Leoni P; Brandozzi G; Federici I; Micucci G; Giantomassi F; Mozzicafreddo G; Alterini R; Filosa G; Ricotti G; Simonacci M; Scortechini AR; Zizzi A; Pimpinelli N
Eur J Dermatol; 2016; 26(1):13-20. PubMed ID: 26678311
[TBL] [Abstract][Full Text] [Related]
16. Role of bath psoralen plus ultraviolet A in early-stage mycosis fungoides.
Pavlotsky F; Hodak E; Ben Amitay D; Barzilai A
J Am Acad Dermatol; 2014 Sep; 71(3):536-41. PubMed ID: 24836546
[TBL] [Abstract][Full Text] [Related]
17. Successful treatment of a folliculotropic mycosis fungoides with bexarotene and PUVA.
Krönke A; Schlaak M; Arin M; Mauch C; Kurschat P
Eur J Dermatol; 2012; 22(2):259-60. PubMed ID: 22240623
[No Abstract] [Full Text] [Related]
18. Follicular mycosis fungoides: successful treatment with oral bexarotene.
Shistik G; Scalf LA; Fenske N; Glass LF
J Drugs Dermatol; 2004; 3(3):301-4. PubMed ID: 15176165
[TBL] [Abstract][Full Text] [Related]
19. Cutaneous T-cell lymphoma treatment using bexarotene and PUVA: a case series.
Singh F; Lebwohl MG
J Am Acad Dermatol; 2004 Oct; 51(4):570-3. PubMed ID: 15389192
[TBL] [Abstract][Full Text] [Related]
20. Management of refractory early-stage cutaneous T-cell lymphoma (mycosis fungoides) with a combination of oral bexarotene and psoralen plus ultraviolet bath therapy.
Huber MA; Kunzi-Rapp K; Staib G; Scharffetter-Kochanek K
J Am Acad Dermatol; 2004 Mar; 50(3):475-6. PubMed ID: 14988696
[No Abstract] [Full Text] [Related]
[Next] [New Search]
